Randomized, Controlled Trials in Health Insurance Systems

Key Points

Key points are not available for this paper at this time.

Abstract

This review article considers the strengths and weaknesses of randomized clinical trials that are conducted through the analysis of data gathered by health insurers.

Read Full Paperexternally

Mark Helpful

Bookmark

Relay

View Full Paper

Cite This Study

Niteesh K. Choudhry (Wed,) studied this question.

synapsesocial.com/papers/6a108cd028c2d29469fe8544 https://doi.org/https://doi.org/10.1056/nejmra1510058

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Economic Outcomes of Treatment Strategies for Type 2 Diabetes Mellitus and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial2009 · 54 citations
2Measuring Costs in Multisite Randomized Controlled Trials1999 · 19 citations
3Rationale and design of the ENhancing outcomes through Goal Assessment and Generating Engagement in Diabetes Mellitus (ENGAGE-DM) pragmatic trial2017 · 6 citations
4Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database1999 · 234 citations
5The Learning Healthcare System: Workshop Summary2013 · 587 citations

Mark Helpful

Bookmark

Relay

View Full Paper